Perhaps indicative of the modest effect of LAG-3 blockade as a monotherapy in human cancers [89] and mouse tumour models [90, 91] complete knockout of LAG-3 in mice displayed normal immune function [10] – in stark contrast to the lymphoproliferative disease observed in CTLA-4 knockout mice [92]. The gene discussed is LAG3; the disease is cancer.